<DOC>
	<DOCNO>NCT00454987</DOCNO>
	<brief_summary>The purpose study evaluate long-term antibody persistence 12 , 24 48 month administration booster dose Menitorix™ , give 12-15 month age . The child previously receive 3 dos Menitorix™ Infanrix™ IPV Meningitec™ Pediacel™ infancy . In addition , antibody persistence investigate child 40-43 month age receive 3-dose primary vaccination MenC conjugate vaccine Hib contain vaccine infancy without booster dose MenC conjugate Hib vaccine second year life . This protocol post deal objective &amp; outcome measure extension phase 12 , 24 48 month booster phase . The objective &amp; outcome measure primary phase &amp; booster phase 12 15 month present separate protocol posting ( NCT number =00258700 ) .</brief_summary>
	<brief_title>Study Long-term Antibody Persistence After Booster Dose Menitorix Vaccine</brief_title>
	<detailed_description>This multicentre &amp; multicountry study open 2 study group Visits 1 3 ( HibMenC LicMenC ) . An additional control group UK time second year follow-up persistence ( subject age 40-43 month prim MenC conjugate Hib vaccine infancy subsequent booster dose , group NoBoost Visit 2 ) . These subject receive Hib catch-up vaccine 40-43 month age . The subject group HibMenC LicMenC randomize primary vaccination study 103974 randomize . The subject group NoBoost randomize . All subject UK centre receive Infanrix™-IPV second visit ( i.e . 24 month Menitorix™ booster 40-43 month age ) . In addition , subject group NoBoost receive Hib catch-up vaccine ( Menitorix™ ) visit . Subjects group HibMenC LicMenC 3 blood sample take immunogenicity analyse : 12 , 24 &amp; 48 month booster vaccination . Subjects group NoBoost 1 blood sample take immunogenicity analyse 40-43 month age . 75 new subject enrol study ( group NoBoost ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Subjects group HibMenC LicMenC Visits 1 , 2 3 : Subjects investigator believe parents/guardians comply requirement protocol . A male female include 24 31 month age time Visit 1 , include 40 43 month age Visit 2 include 60 64 month Visit 3 . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Having complete booster vaccination study 104056 . Subjects group NoBoost Visit 2 ( UK ) : Subjects investigator believe parents/guardians comply requirement protocol . A male female include 40 43 month age Visit 2 . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Having receive 3dose primary vaccination MenC conjugate vaccine Hib contain vaccine age 8 month . Previous administration booster dose Hib meningococcal serogroup C except booster study vaccine study 104056 . History H. influenzae type b meningococcal disease . For UK subject group HibMenC LicMenC : previous administration booster dose pertussiscontaining vaccine except booster study vaccine study 104056 .</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>64 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>antibody persistence</keyword>
	<keyword>Meningococcal serogroup C vaccine</keyword>
	<keyword>conjugate vaccine</keyword>
	<keyword>Haemophilus influenzae type b vaccine</keyword>
</DOC>